Health and Fitness Health and Fitness
Wed, September 15, 2010
[ Wed, Sep 15th 2010 ] - Market Wire
Covidien annonce les points forts de sa r©union avec les investisseurs
[ Wed, Sep 15th 2010 ] - Market Wire
Covidien Announces Highlights from Investor Meeting
[ Wed, Sep 15th 2010 ] - Market Wire
Forest Laboratories, Inc. Finalizes Previously Di .. vernment Investigations and Related Civil Qui Tam
[ Wed, Sep 15th 2010 ] - Market Wire
Healthways Ranks #8 on 2010 InformationWeek 500
[ Wed, Sep 15th 2010 ] - Market Wire
Crozer-Keystone Health System Joins Aetna Better Health Network
[ Wed, Sep 15th 2010 ] - Market Wire
Impax Laboratories to Present at the UBS Global Life Sciences Conference
[ Wed, Sep 15th 2010 ] - Market Wire
Bond Labs Expands Resurrection(TM) into the Atlanta and Savannah Markets
[ Wed, Sep 15th 2010 ] - Market Wire
BioCryst to Present Peramivir Data at the 50th Annual ICAAC Meeting
[ Wed, Sep 15th 2010 ] - Market Wire
Micromet to Present at the 2010 UBS Global Life Sciences Conference
[ Wed, Sep 15th 2010 ] - Market Wire
Medical Action Industries to Present in the 2010 UBS Global Life Sciences Conference
[ Wed, Sep 15th 2010 ] - Market Wire
Celgene Corporation to Present at the UBS 2010 Global Life Sciences Conference
[ Wed, Sep 15th 2010 ] - Market Wire
ArthroCare to Present at UBS Global Life Sciences Conference
[ Wed, Sep 15th 2010 ] - Market Wire
BioCryst Reports Results from Two Forodesine Oncology Studies
[ Wed, Sep 15th 2010 ] - Market Wire
SuperGen to Present at UBS Global Life Sciences Conference on September 22nd
[ Wed, Sep 15th 2010 ] - Market Wire
Four Rivers Announces Licensure of STT Technology .. Gain, Reduction of Overhead Costs and Future Prof
Tue, September 14, 2010
[ Tue, Sep 14th 2010 ] - Market Wire
Law Offices of Howard G. Smith Announces Investig .. lf of Shareholders of Acura Pharmaceuticals, Inc.
[ Tue, Sep 14th 2010 ] - Market Wire
Law Offices of Howard G. Smith Announces Investig .. n On Behalf of Shareholders of ZymoGenetics, Inc.
[ Tue, Sep 14th 2010 ] - Market Wire
Micrus Announces Stockholder Approval of Merger Agreement with Johnson & Johnson
[ Tue, Sep 14th 2010 ] - Market Wire
Laboratory Corporation of America Holdings, Genzy .. ger Company, Wal-Mart Stores and Costco Wholesale
[ Tue, Sep 14th 2010 ] - Market Wire
Celera to Webcast Its Presentation at the UBS Global Life Sciences Conference
[ Tue, Sep 14th 2010 ] - Market Wire
NPS Pharmaceuticals to Present at UBS Global Life Sciences Conference
[ Tue, Sep 14th 2010 ] - Market Wire
Alnylam to Webcast Presentation at UBS Global Life Sciences Conference
[ Tue, Sep 14th 2010 ] - Market Wire
Human Genome Sciences Invites Investors to Listen .. entation at Stifel Nicolaus Healthcare Conference
[ Tue, Sep 14th 2010 ] - Market Wire
Law Office of Jonathan M. Stein, P.L. Investigate .. ary Duty by the Officers and Directors of Acura P
[ Tue, Sep 14th 2010 ] - Market Wire
Medtronic CFO Gary Ellis to Speak at UBS Global Life Sciences Conference
[ Tue, Sep 14th 2010 ] - Market Wire
American Medical Systems Receives Favorable Ruling in Patent Lawsuit against Biolitec
[ Tue, Sep 14th 2010 ] - Market Wire
Synergy Pharmaceuticals participa en el Simposio Roche Colorado Corporation Peptide 2010
[ Tue, Sep 14th 2010 ] - Market Wire
Aetna Wins Contract for Illinois Managed Medicaid Pilot Program
[ Tue, Sep 14th 2010 ] - Market Wire
The Briscoe Law Firm and Powers Taylor, LLP Inves .. Fiduciary Duties by the Officers and Directors of
[ Tue, Sep 14th 2010 ] - Market Wire
El tratamiento VIH de nico comprimido "Quad" de G .. in viral durante 48 semanas en estudio de fase II

El tratamiento VIH de nico comprimido "Quad" de Gilead consigue alta supresin viral durante 48 semanas en estudio de fase II


Published on 2010-09-14 07:45:23 - Market Wire
  Print publication without navigation


FOSTER CITY, California--([ BUSINESS WIRE ])--Gilead Sciences, Inc. (Nasdaq:GILD) ha comunicado los resultados del ensayo clnico de fase II que revelan que su tratamiento en fase de investigacin, de dosis fija y nico comprimido, "Quad" de elvitegravir, cobicistat y Truvada� (emtricitabina y fumarato de tenofovir disoproxil) para el tratamiento de infecciones VIH ha conseguido una tasa alta de supresin virolgica durante 48 semanas, demostrando una actividad antirretroviral comparable a la de Atripla� (efavirenz 600 mg/emtricitabina 200 mg/ fumarato de tenofovir disoproxil 300 mg).

El comunicado en el idioma original, es la versin oficial y autorizada del mismo. La traduccin es solamente un medio de ayuda ydeber sercomparada con el texto en idioma original, que es la nica versin del texto que tendr validez legal.

Contributing Sources